Business Description
Corbus Pharmaceuticals Holdings Inc
NAICS : 325414
SIC : 2834
ISIN : US21833P1030
Total Employee Number:
36Description
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 114.71 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 10.4 | |||||
3-Year EPS without NRI Growth Rate | 12.7 | |||||
3-Year FCF Growth Rate | 18.7 | |||||
3-Year Book Growth Rate | 1.9 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 77.67 | |||||
9-Day RSI | 70.3 | |||||
14-Day RSI | 62.55 | |||||
3-1 Month Momentum % | -21.57 | |||||
6-1 Month Momentum % | -7.54 | |||||
12-1 Month Momentum % | 2.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.92 | |||||
Quick Ratio | 7.92 | |||||
Cash Ratio | 7.62 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -61.6 | |||||
Shareholder Yield % | 2.43 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -69.96 | |||||
ROA % | -61.5 | |||||
ROIC % | -1713.9 | |||||
3-Year ROIIC % | 711.92 | |||||
ROC (Joel Greenblatt) % | -5522.45 | |||||
ROCE % | -70.8 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.34 | |||||
Price-to-Tangible-Book | 1.34 | |||||
EV-to-EBIT | -0.46 | |||||
EV-to-Forward-EBIT | -0.4 | |||||
EV-to-EBITDA | -0.46 | |||||
EV-to-Forward-Revenue | 0.59 | |||||
EV-to-FCF | -0.54 | |||||
| Price-to-Net-Current-Asset-Value | 1.35 | |||||
| Price-to-Net-Cash | 1.41 | |||||
Earnings Yield (Greenblatt) % | -217.39 | |||||
FCF Yield % | -41.67 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Corbus Pharmaceuticals Holdings Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -4.998 | ||
| Beta | 24.0546 | ||
| 3-Year Sharpe Ratio | 0.54 | ||
| 3-Year Sortino Ratio | 9.69 | ||
| Volatility % | 66.94 | ||
| 14-Day RSI | 62.55 | ||
| 14-Day ATR (€) | 0.417748 | ||
| 20-Day SMA (€) | 7.47725 | ||
| 12-1 Month Momentum % | 2.58 | ||
| 52-Week Range (€) | 5.9 - 21 | ||
| Shares Outstanding (Mil) | 18.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Corbus Pharmaceuticals Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Corbus Pharmaceuticals Holdings Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 126 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 27 days | ||
| Jefferies Global Healthcare Conference | 2026-06-04 16:55 | 6.31 (-0.94%) | ||
| Guidance call for 2026 | 2026-05-26 08:00 | 9.65 (+0.16%) | ||
| RBC Capital Markets Global Healthcare Conference | 2026-05-19 14:05 | 8.45 (-9.44%) | ||
| General meeting for 2026 | 2026-05-13 09:00 | 9.39 (+1.51%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 9.24 (+1.32%) | ||
| Annual report for 2025 | 2026-03-09 | 7.00 (+2.94%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-09 | 7.00 (+2.94%) | ||
| 36th Annual Oppenheimer Healthcare Life Sciences Conference | 2026-02-25 15:20 | 6.45 (+4.03%) |
Show
Entries
Corbus Pharmaceuticals Holdings Inc Frequently Asked Questions
What is Corbus Pharmaceuticals Holdings Inc(STU:3371)'s stock price today?
The current price of STU:3371 is €8.36. The 52 week high of STU:3371 is €21.00 and 52 week low is €5.90.
When is next earnings date of Corbus Pharmaceuticals Holdings Inc(STU:3371)?
The next earnings date of Corbus Pharmaceuticals Holdings Inc(STU:3371) is 2026-08-05 Est..
Does Corbus Pharmaceuticals Holdings Inc(STU:3371) pay dividends? If so, how much?
Corbus Pharmaceuticals Holdings Inc(STU:3371) does not pay dividend.
Press Release
Articles on Corbus Pharmaceuticals Holdings Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers